Resumen de acción ADAP
Adaptimmune Therapeutics plc, empresa biofarmacéutica en fase clínica, ofrece nuevas terapias celulares principalmente a pacientes con cáncer en Estados Unidos y Reino Unido.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Recompensas
Análisis de riesgos
+ 1 riesgos adicionales
Competidores de Adaptimmune Therapeutics plc
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.21 |
| 52 Week High | US$2.05 |
| 52 Week Low | US$0.42 |
| Beta | 2.38 |
| 1 Month Change | -17.69% |
| 3 Month Change | 21.00% |
| 1 Year Change | -13.57% |
| 3 Year Change | -76.37% |
| 5 Year Change | -71.99% |
| Change since IPO | -92.98% |
Noticias y actualizaciones recientes
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16
Recent updates
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14Adaptimmune Therapeutics: T-Cell Therapy Pioneer Boasts A Deep Pipeline, ESMO Approaches
Jul 29Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts
Jun 16Adaptimmune Therapeutics (ADAP) Investor Presentation - Slideshow
Jun 05Adaptimmune slips as Barclays initiates with an underweight rating
May 28We Think Adaptimmune Therapeutics (NASDAQ:ADAP) Can Easily Afford To Drive Business Growth
Apr 15Investors Who Bought Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Are Now Up 101%
Mar 15Is Adaptimmune Therapeutics plc (NASDAQ:ADAP) Popular Amongst Institutions?
Feb 17
Have Adaptimmune Therapeutics plc (NASDAQ:ADAP) Insiders Been Selling Their Stock?
Jan 22Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Strong Position To Grow Its Business
Jan 15Adaptimmune Therapeutics (NASDAQ:ADAP) Shareholders Have Enjoyed An Impressive 227% Share Price Gain
Dec 11Rentabilidad de los accionistas
| ADAP | US Biotechs | Mercado US | |
|---|---|---|---|
| 7D | 12.0% | -1.5% | -0.7% |
| 1Y | -13.6% | 0.1% | 22.3% |
Rentabilidad vs. Industria: ADAP obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del -2.3%.
Rentabilidad vs. Mercado: ADAP obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.
Volatilidad de los precios
| ADAP volatility | |
|---|---|
| ADAP Average Weekly Movement | 15.3% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: El precio de las acciones de ADAP ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de ADAP(16%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2008 | 449 | Ad Rawcliffe | www.adaptimmune.com |
Adaptimmune Therapeutics plc, empresa biofarmacéutica en fase clínica, ofrece nuevas terapias celulares principalmente a pacientes con cáncer en Estados Unidos y el Reino Unido. Desarrolla SPEARHEAD-1, en fase II de ensayos clínicos con ADP-A2M4 para el sarcoma sinovial; SURPASS-3, en fase II de ensayos clínicos con ADP-A2M4CD8 para personas con cáncer de ovario resistente al platino; y SURPASS, en fase I de ensayos clínicos en pacientes con cáncer de cabeza y cuello y urotelio. La empresa tiene un acuerdo estratégico de colaboración y licencia con Genentech, Inc. y F. Hoffman-La Roche Ltd para desarrollar terapias personalizadas de células T alogénicas y alogénicas; un acuerdo de investigación, colaboración y licencia con Universal Cells, Inc.; colaboraciones de terceros con Noile-Immune y Alpine Immune Sciences; y un acuerdo de alianza estratégica con el MD Anderson Cancer Center.
Resumen de fundamentos de Adaptimmune Therapeutics plc
| Estadísticas fundamentales de ADAP | |
|---|---|
| Capitalización bursátil | US$304.12m |
| Beneficios(TTM) | -US$113.87m |
| Ingresos (TTM) | US$60.28m |
5.1x
Ratio precio-ventas (PS)-2.7x
Ratio precio-beneficio (PE)¿Está ADAP sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de ADAP | |
|---|---|
| Ingresos | US$60.28m |
| Coste de los ingresos | US$126.51m |
| Beneficio bruto | -US$66.23m |
| Otros gastos | US$47.64m |
| Beneficios | -US$113.87m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
May 15, 2024
| Beneficios por acción (BPA) | -0.45 |
| Margen bruto | -109.87% |
| Margen de beneficio neto | -188.90% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado ADAP a largo plazo?
Ver rendimiento histórico y comparativa